Multiple analyses of TE with delayed entry at day 29 (N = 1594)
| . | N . | TE-specific HRa . | 95% CI . | P . |
|---|---|---|---|---|
| Age groups | ||||
| 1.0-9.9 y | 1116 | 1.00 [ref.] | ||
| 10.0-17.9 y | 274 | 4.9 | 3.1-7.8 | <.0001 |
| 18.0-45.9 y | 204 | 6.1 | 3.7-10.1 | <.0001 |
| Sex | ||||
| Female | 715 | 1.00 [ref.] | ||
| Male | 879 | 1.3 | 0.9-2.0 | .1 |
| BMI | ||||
| >−2SD to <+2SD | 79 | 1.00 [ref.] | ||
| ≤−2SD | 1412 | 1.4 | 0.6-3.2 | .5 |
| ≥+2SD | 103 | 0.8 | 0.4-1.5 | .4 |
| WBC | ||||
| <100 × 109/L | 1396 | 1.00 [ref.] | ||
| ≥100 × 109/L | 198 | 1.0 | 0.5-2.1 | >.9 |
| Immunophenotype | ||||
| BCP | 1361 | 1.00 [ref.] | ||
| T-cell | 233 | 1.3 | 0.4-4.1 | .7 |
| CNS status | ||||
| CNS1 | 1397 | 1.00 [ref.] | ||
| CNS2/CNS3 | 197 | 0.9 | 0.4-1.6 | .6 |
| Mediastinal mass | ||||
| No | 1468 | 1.00 [ref.] | ||
| Yes | 126 | 2.1 | 1.0-4.3 | .04 |
| Enlarged lymph nodes ≥3 cm | ||||
| No | 1480 | 1.00 [ref.] | ||
| Yes | 114 | 1.3 | 0.7-2.4 | .4 |
| Palpable splenomegaly | ||||
| No | 1351 | 1.00 [ref.] | ||
| Yes | 243 | 1.3 | 0.8-2.0 | .3 |
| Induction | ||||
| Dexamethasone | 323 | 1.00 [ref.] | ||
| Prednisolone | 1271 | 1.4 | 0.4-4.4 | .6 |
| Antithrombotic prophylaxis | ||||
| No | 1555 | 1.00 [ref.] | ||
| Yes | 39 | 0.8 | 0.3-1.9 | .6 |
| MRD day 29 | ||||
| <0.001 | 1095 | 1.00 [ref.] | ||
| ≥0.001 to <0.05 | 425 | 1.1 | 0.6-2.0 | .7 |
| ≥0.05 | 74 | 2.3 | 0.7-7.0 | .2 |
| Treatment group day 29 | ||||
| SR | 741 | 1.00 [ref.] | ||
| IR | 611 | 0.9 | 0.5-1.6 | .8 |
| HR/HR-SCT | 242 | 0.5 | 0.2-1.4 | .2 |
| . | N . | TE-specific HRa . | 95% CI . | P . |
|---|---|---|---|---|
| Age groups | ||||
| 1.0-9.9 y | 1116 | 1.00 [ref.] | ||
| 10.0-17.9 y | 274 | 4.9 | 3.1-7.8 | <.0001 |
| 18.0-45.9 y | 204 | 6.1 | 3.7-10.1 | <.0001 |
| Sex | ||||
| Female | 715 | 1.00 [ref.] | ||
| Male | 879 | 1.3 | 0.9-2.0 | .1 |
| BMI | ||||
| >−2SD to <+2SD | 79 | 1.00 [ref.] | ||
| ≤−2SD | 1412 | 1.4 | 0.6-3.2 | .5 |
| ≥+2SD | 103 | 0.8 | 0.4-1.5 | .4 |
| WBC | ||||
| <100 × 109/L | 1396 | 1.00 [ref.] | ||
| ≥100 × 109/L | 198 | 1.0 | 0.5-2.1 | >.9 |
| Immunophenotype | ||||
| BCP | 1361 | 1.00 [ref.] | ||
| T-cell | 233 | 1.3 | 0.4-4.1 | .7 |
| CNS status | ||||
| CNS1 | 1397 | 1.00 [ref.] | ||
| CNS2/CNS3 | 197 | 0.9 | 0.4-1.6 | .6 |
| Mediastinal mass | ||||
| No | 1468 | 1.00 [ref.] | ||
| Yes | 126 | 2.1 | 1.0-4.3 | .04 |
| Enlarged lymph nodes ≥3 cm | ||||
| No | 1480 | 1.00 [ref.] | ||
| Yes | 114 | 1.3 | 0.7-2.4 | .4 |
| Palpable splenomegaly | ||||
| No | 1351 | 1.00 [ref.] | ||
| Yes | 243 | 1.3 | 0.8-2.0 | .3 |
| Induction | ||||
| Dexamethasone | 323 | 1.00 [ref.] | ||
| Prednisolone | 1271 | 1.4 | 0.4-4.4 | .6 |
| Antithrombotic prophylaxis | ||||
| No | 1555 | 1.00 [ref.] | ||
| Yes | 39 | 0.8 | 0.3-1.9 | .6 |
| MRD day 29 | ||||
| <0.001 | 1095 | 1.00 [ref.] | ||
| ≥0.001 to <0.05 | 425 | 1.1 | 0.6-2.0 | .7 |
| ≥0.05 | 74 | 2.3 | 0.7-7.0 | .2 |
| Treatment group day 29 | ||||
| SR | 741 | 1.00 [ref.] | ||
| IR | 611 | 0.9 | 0.5-1.6 | .8 |
| HR/HR-SCT | 242 | 0.5 | 0.2-1.4 | .2 |
ref., reference.